Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

December 09, 2025 09:58 ET | Source: Research and Markets

Global Market for Merkel Cell Carcinoma Driven by Key Players Like Merck & Bristol Myers Squibb

Dublin, Dec. 09, 2025 (GLOBE NEWSWIRE) -- The "Merkel Cell Carcinoma Market - A Global and Regional Analysis: Focus on Country and Region - Analysis and Forecast, 2025-2035" has been added to ...
December 09, 2025 07:18 ET | Source: Formycon AG

Formycon and Zydus partner for exclusive licensing and supply agreement of FYB206, a biosimilar to Keytruda® (Pembrolizumab), in the U.S. and Canada

Licensing partner Zydus brings extensive commercial experience, marketing more than 225 FDA-approved medicines, providing a strong foundation for a successful launch of FYB206Strong early partnering...
July 25, 2025 05:25 ET | Source: Research and Markets

U.S. Keytruda Market Research Report 2025 | Merck's Keytruda Faces Challenges as Patent Expiry Approaches in 2028 - Forecast to 2033

Dublin, July 25, 2025 (GLOBE NEWSWIRE) -- The "U.S. Keytruda Market Size, Share & Trends Analysis Report By Application (Lung Cancer, Breast Cancer, Melanoma, Hodgkin Lymphoma, Head & Neck...
April 14, 2025 04:16 ET | Source: Research and Markets

Keytruda Market to Reach $26.6 Billion by 2030 Amid Patent Expiry & Biosimilar Challenges

Dublin, April 14, 2025 (GLOBE NEWSWIRE) -- The "Keytruda Market Size, Share & Trends Analysis Report By Application (Lung Cancer, Breast Cancer, Melanoma, Hodgkin Lymphoma), By Payer...
November 05, 2024 08:30 ET | Source: Vaccinex, Inc.

Vaccinex Reports Improved Immunity Correlating with Clinical Benefit of Pepinemab Combination Treatment at Society for Immunotherapy of Cancer’s Annual Meeting

ROCHESTER, N.Y., Nov. 05, 2024 (GLOBE NEWSWIRE) -- Vaccinex, Inc. (Nasdaq: VCNX), a clinical-stage biotechnology company pioneering a differentiated approach to treating cancer and neurodegenerative...
September 18, 2024 08:30 ET | Source: Vaccinex, Inc.

Vaccinex Announces Exercise of Warrants for $6.2 Million in Gross Proceeds

ROCHESTER, N.Y., Sept. 18, 2024 (GLOBE NEWSWIRE) -- Vaccinex, Inc. (Nasdaq: VCNX) (“Vaccinex” or the “Company”), a clinical-stage biotechnology company pioneering a differentiated approach to...
December 04, 2023 08:00 ET | Source: Vaccinex, Inc.

Nasdaq Grants Vaccinex Extension Until March 4, 2024 to Regain Compliance with Listing Rule

Company Has Reassured Nasdaq of Actions It Plans to Take to Meet Minimum Bid Price Requirement Randomized Phase 2 Study in Alzheimer’s Disease on Schedule to Complete Treatment in June 2024 ...
November 27, 2023 10:03 ET | Source: Research and Markets

KEYTRUDA Drug Insight and Market Forecast Report, 2019-2022 & 2023-2032: Focus on 7 Major Markets - United States, Germany, France, Italy, Spain, United Kingdom, and Japan

Dublin, Nov. 27, 2023 (GLOBE NEWSWIRE) -- The "KEYTRUDA Drug Insight and Market Forecast - 2032" report has been added to ResearchAndMarkets.com's offering.This report provides comprehensive...
November 13, 2023 08:00 ET | Source: Vaccinex, Inc.

Vaccinex Reports Third Quarter 2023 Financial Results and Provides Corporate Update

Phase 1/2a Randomized SIGNAL-AD Study of Pepinemab in Alzheimer’s Disease Achieves Full Accrual Expect to Complete 12-months treatment in June, 2024 Company raised over $10 million of new...
September 28, 2023 21:00 ET | Source: Vaccinex, Inc.

Vaccinex Announces Pricing of $9.6 Million Public Offering

ROCHESTER, N.Y., Sept. 28, 2023 (GLOBE NEWSWIRE) -- Vaccinex, Inc. (Nasdaq: VCNX) (“Vaccinex” or the “Company”), a clinical-stage biotechnology company pioneering a differentiated approach to...